<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299906</url>
  </required_header>
  <id_info>
    <org_study_id>FCRE-191127</org_study_id>
    <nct_id>NCT04299906</nct_id>
    <nct_alias>NCT04545281</nct_alias>
  </id_info>
  <brief_title>SOLARIS Peripheral PMCF Trial</brief_title>
  <official_title>Physician-Initiated PMCF Trial Investigating the Solaris Vascular Stent Graft for the Treatment of Iliac Lesions - SOLARIS Peripheral PMCF Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Giovanni Torsello</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FCRE (Foundation for Cardiovascular Research and Education)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scitech Produtos Medicos Ltda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>FCRE (Foundation for Cardiovascular Research and Education)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical investigation is to evaluate, in a controlled setting, the&#xD;
      long-term (up to 12 months) safety and efficacy of the Solaris Vascular Stent Graft (Scitech)&#xD;
      in clinical settings when used according to the indications of the IFU.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency Rate at 12 month follow-up</measure>
    <time_frame>12 months post-op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Patency Rate at 1- and 6 month follow-up</measure>
    <time_frame>1 monthand 6 months post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Graft Occlusion Rate at pre-discharge, 1-, 6-, and 12-month follow-up</measure>
    <time_frame>1day, 1 month, 6 month and 12 month post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-Brachial Index at 1-, 6- and 12-month follow-up compared with baseline ABI</measure>
    <time_frame>1-, 6- and 12-month post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation rate at 1-, 6- and 12-month follow-up, defined as any amputation above the knee</measure>
    <time_frame>1-, 6- and 12-month post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance success rate at baseline</measure>
    <time_frame>during procedure</time_frame>
    <description>defined as a composite of (a) successful in sealing acute perforation or rupture; (b) successful in treating aneurysm and fistulae ; (c) restoration of blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in-stent restenosis rate at 1-, 6- and 12-month post-op</measure>
    <time_frame>1-, 6-, 12-month post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Target Lesion Revascularization at 1-, 6- and 12-month post-op</measure>
    <time_frame>1-, 6- and 12-month post-op</time_frame>
    <description>defined as freedom from a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAE's) until 12-month post-op</measure>
    <time_frame>within 12-months post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>during procedure</time_frame>
    <description>defined as the ability to achieve final residual angiographic stenosis no greater than 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success at follow-up</measure>
    <time_frame>1-, 6- and 12-month post-op</time_frame>
    <description>defined as an improvement of Rutheford Classification at 1-, 6- and 12-month follow-up of one class or more as compared to the pre-procedure Rutherford classification</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Iliac Artery Stenosis</condition>
  <condition>Common Femoral Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Solaris Vascular Stent Graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implant of Solaris Vascular Stent Graft in aorto-iliac lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Solaris Vascular Stent Graft</intervention_name>
    <description>Solaris Vascular Stent Graft for treatment of Iliac Lesions</description>
    <arm_group_label>Solaris Vascular Stent Graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Corresponding to the IFU indications/contra-indications and according to the current&#xD;
             medical guidelines for minimally invasive peripheral interventions.&#xD;
&#xD;
          -  Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable&#xD;
             for stenting (on indication for primary stenting, based on the discretion of the&#xD;
             investigator)&#xD;
&#xD;
          -  Patient presenting a score from 2 to 5 following Rutherford classification&#xD;
&#xD;
          -  Patient is willing to comply with specified follow-up evaluations at the specified&#xD;
             times for the duration of the study&#xD;
&#xD;
          -  Patient is &gt;18 years old&#xD;
&#xD;
          -  Patient (or their legal representative) understands the nature of the procedure and&#xD;
             provides written informed consent, prior to enrolment in the study&#xD;
&#xD;
          -  The target lesion is either a modified TASC-II class A, B, C or D lesion.&#xD;
&#xD;
          -  The target lesion has angiographic evidence of stenosis or restenosis &gt; 50% or&#xD;
             occlusion which can be passed with standard guidewire manipulation&#xD;
&#xD;
          -  There is angiographic evidence of a patent Common and Deep Femoral Artery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PTA is technically not possible (not feasible to access the lesion or a defect with&#xD;
             the guidewire or balloon catheter)&#xD;
&#xD;
          -  Presence of an aneurysm immediately adjacent to the site of stent implantation&#xD;
&#xD;
          -  Stenosis distal to the site of stent implantation&#xD;
&#xD;
          -  Lesions in or adjacent to essential collaterals(s)&#xD;
&#xD;
          -  Lesions in locations subject to external compression&#xD;
&#xD;
          -  Heavily calcified lesions resistant to PTA&#xD;
&#xD;
          -  Patients with diffuse distal disease resulting in poor stent outflow&#xD;
&#xD;
          -  Patients with a history of coagulation disorders&#xD;
&#xD;
          -  Patients with aspirin allergy or bleeding complications and patients unable or&#xD;
             unwilling to tolerate anticoagulant/antiplatelet therapy and/or non-responders to&#xD;
             anticoagulant/antiplatelet therapy&#xD;
&#xD;
          -  Fresh thrombus formation&#xD;
&#xD;
          -  Patients with known hypersensitivity to the stent material (L605) and/or PTFE&#xD;
&#xD;
          -  The target lesion is either a modified TASC-II class B or D lesion with aortic or&#xD;
             common femoral lesion involvement.&#xD;
&#xD;
          -  Previously implanted stent(s) at the same lesion site&#xD;
&#xD;
          -  Reference segment diameter is not suitable for the available stent design&#xD;
&#xD;
          -  Untreatable lesion located at the distal outflow arteries&#xD;
&#xD;
          -  Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation&#xD;
             therapy) as part of the index procedure&#xD;
&#xD;
          -  Patients refusing treatment&#xD;
&#xD;
          -  Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are&#xD;
             contraindicated&#xD;
&#xD;
          -  Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion&#xD;
             site&#xD;
&#xD;
          -  Perforation at the angioplasty site evidenced by extravasation of contrast medium&#xD;
&#xD;
          -  Patients with a history of prior life-threatening contrast medium reaction&#xD;
&#xD;
          -  Patients with uncorrected bleeding disorders&#xD;
&#xD;
          -  Female patient with child bearing potential not taking adequate contraceptives or&#xD;
             currently breastfeeding&#xD;
&#xD;
          -  Life expectancy of less than twelve months&#xD;
&#xD;
          -  Any planned surgical intervention/procedure within 30 days of the study procedure&#xD;
&#xD;
          -  Any patient considered to be hemodynamically unstable at onset of procedure&#xD;
&#xD;
          -  Patient is currently participating in another investigational drug or device study&#xD;
             that has not completed the entire follow up period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Torsello, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>FCRE (Foundation for Cardiovascular Research and Education)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annelena Held-Wehmöller</last_name>
    <phone>+4915785128140</phone>
    <email>info@fcre.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saarland University Medical Center</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Maßmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dierk Scheinert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Franziskus Hospital</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Bosiers, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Oberhuber</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MCL Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cora Arts</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olaf Bakker</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>FCRE (Foundation for Cardiovascular Research and Education)</investigator_affiliation>
    <investigator_full_name>Prof. Giovanni Torsello</investigator_full_name>
    <investigator_title>Study Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

